German drug and crop chemical group Bayer AG on Thursday announced details of a sweetened 64 billion bid for Monsanto Co. as it tries to put the U.S. seed company under pressure to engage further. Analysts and some Monsanto shareholders were quick to opine that Bayer's latest offer, the largest all-cash takeover bid on record, was unlikely to entice Monsanto. Bayer, however, is hoping that the sweetened offer will spur enough Monsanto shareholders to call on the company's management to be more accommodative. Global agrochemicals companies are racing to consolidate, partly in response to a drop in commodity prices that has hit farm incomes. Bayer made its bid for Monsanto public in May, but the two companies have made little progress since in negotiating a deal.
Bayer's planned $62.5 billion takeover of seeds maker Monsanto is set to close on Thursday, Germany's Frankfurter Allgemeine Sonntags Zeitung reported. A Bayer spokesman declined to comment on the Sunday newspaper report. Bayer last week won U.S. approval for the Monsanto takeover after months of delays in a drawn-out review, clearing a major hurdle for a deal that will create by far the largest seeds and pesticides maker. Bayer has said it would very soon close the transaction, which it needs to do because after June 14, Monsanto could withdraw from the takeover agreement and seek a higher price. A woman uses a Monsanto's Roundup weedkiller spray without glyphosate in a garden in Ercuis near Paris.
Monsanto has rejected a 62bn ( 43bn) offer from Bayer that would have created the world's biggest agricultural supplier. The US company said he offer was "financially inadequate", but left the door open for a potentially higher bid. High Grant, Monsanto chief executive, said the proposal significantly undervalued the company. He also raised concerns about whether a deal would be approved by regulators. Monsanto shares rose almost 3% to 109.11 in afternoon trading in New York.
Some companies' reputations are so poor that the public already has low expectations when it comes to their ethics and business practices. That doesn't make it any less shocking when the accusations against them are confirmed in black and white. Agricultural chemicals giant Monsanto is under fire because the company's herbicide, Roundup (active ingredient: glyphosate), is suspected of being carcinogenic. Permission to sell the chemical in the European Union expires on December 15 with member states set to decide on Wednesday whether to renew it for another 10 years. And now, the longstanding dispute about glyphosate has been brought to a head by the release of explosive documents.